Skip to content

Released Mar 31, 2022, after the close

10-K filed Mar 31, 2022, 90 days after period end · 0001390478-22-000006

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derived−100.0% vs Q4 2020no prior Q3 2021 on file
Net Income-$6.60MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$11,619,000N/M
Operating Cash Flowderived-$4,976,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019derived from reported figuresQ4 2018derived from reported figures
Revenue$0.00$1.90M——
Net Income-$6.60M-$3.72M-$7.42M-$13.32M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR